MX2022009836A - Vacuna para sars-cov-2. - Google Patents

Vacuna para sars-cov-2.

Info

Publication number
MX2022009836A
MX2022009836A MX2022009836A MX2022009836A MX2022009836A MX 2022009836 A MX2022009836 A MX 2022009836A MX 2022009836 A MX2022009836 A MX 2022009836A MX 2022009836 A MX2022009836 A MX 2022009836A MX 2022009836 A MX2022009836 A MX 2022009836A
Authority
MX
Mexico
Prior art keywords
cov
sars
vaccine
subject
nucleic acid
Prior art date
Application number
MX2022009836A
Other languages
English (en)
Inventor
Barney Graham
Jason Mclellan
Kizzmekia Corbett
Olubukola Abiona
Geoffrey Hutchinson
Daniel Wrapp
Nianshuang Wang
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2022009836A publication Critical patent/MX2022009836A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen trímeros de ectodominio S de SARS-CoV-2 estabilizados en una conformación de prefusión, moléculas de ácido nucleico y vectores que codifican estas proteínas, y métodos de su uso y producción. En varias modalidades, los trímeros de ectodominio S de SARS-CoV-2 y/o moléculas de ácido nucleico se pueden utilizar para generar una respuesta inmune a S de SARS-CoV-2 en un sujeto, por ejemplo, una respuesta inmune que inhibe la infección de SARS-CoV-2 en el sujeto.
MX2022009836A 2020-02-11 2021-02-11 Vacuna para sars-cov-2. MX2022009836A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972886P 2020-02-11 2020-02-11
PCT/US2021/017709 WO2021163365A1 (en) 2020-02-11 2021-02-11 Sars-cov-2 vaccine

Publications (1)

Publication Number Publication Date
MX2022009836A true MX2022009836A (es) 2022-11-30

Family

ID=74860458

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009836A MX2022009836A (es) 2020-02-11 2021-02-11 Vacuna para sars-cov-2.

Country Status (11)

Country Link
US (1) US20230113170A1 (es)
EP (1) EP4103229A1 (es)
JP (1) JP2023513693A (es)
KR (1) KR20220140586A (es)
CN (1) CN115515627A (es)
AU (1) AU2021221127A1 (es)
BR (1) BR112022015628A2 (es)
CA (1) CA3170322A1 (es)
IL (1) IL295301A (es)
MX (1) MX2022009836A (es)
WO (1) WO2021163365A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210260181A1 (en) * 2014-09-16 2021-08-26 Altimmune, Inc Coronavirus immunogenic compositions and uses thereof
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
BR112022019781A2 (pt) * 2020-04-22 2022-12-13 BioNTech SE Vacina para o coronavírus
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
CN113633764B (zh) * 2021-09-02 2024-05-14 中国食品药品检定研究院 一种含佐剂的新冠dna疫苗
CN113527522B (zh) * 2021-09-13 2021-12-21 深圳市瑞吉生物科技有限公司 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗
WO2023047348A1 (en) * 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) * 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
CA3234578A1 (en) 2021-10-22 2023-04-27 Advait Vijay Badkar Compositions for administration of different doses of rna
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
JP2023081859A (ja) 2021-11-29 2023-06-13 ビオンテック・ソシエタス・エウロパエア コロナウイルスワクチン
WO2023094885A2 (en) * 2021-11-29 2023-06-01 Arabian Gulf University Antigenic determinants, protective immunity, serodiagnostic and multivalent subunits precision vaccine against sars-cov-2
CN114989308B (zh) * 2022-05-12 2023-04-04 中国科学院微生物研究所 新冠病毒嵌合核酸疫苗及其用途
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN115287265B (zh) * 2022-07-12 2023-05-23 四川大学华西医院 多能活性制剂诱发恒河猴抵抗新冠突变体的免疫防治模型
WO2024086575A1 (en) 2022-10-17 2024-04-25 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP0667912B1 (fr) 1993-07-13 2008-07-02 Centelion Vecteurs adenoviraux defectifs et utilisation en therapie genique
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
WO2003022311A1 (en) 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
EP3532095A1 (en) * 2016-10-25 2019-09-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Prefusion coronavirus spike proteins and their use

Also Published As

Publication number Publication date
US20230113170A1 (en) 2023-04-13
AU2021221127A1 (en) 2022-09-22
CN115515627A (zh) 2022-12-23
JP2023513693A (ja) 2023-04-03
KR20220140586A (ko) 2022-10-18
IL295301A (en) 2022-10-01
WO2021163365A1 (en) 2021-08-19
EP4103229A1 (en) 2022-12-21
BR112022015628A2 (pt) 2022-09-27
CA3170322A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
MX2022009836A (es) Vacuna para sars-cov-2.
WO2016037154A8 (en) Recombinant hiv-1 envelope proteins and their use
MX2021010519A (es) Proteinas f de rsv de prefusion y su uso.
MX2022003994A (es) Produccion de oligosacaridos de leche humana en huespedes microbianos con importacion/exportacion dise?ada.
MX2023008626A (es) Proteinas klotho recombinantes terapeuticas y composiciones y metodos que involucran a las mismas.
BR112018070323A2 (pt) vacina contra rsv
PH12018501047A1 (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
MX2018001567A (es) Novedosos polipeptidos de fusion especificos para lag-3 y pd-1.
MX352974B (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
EA201891945A2 (ru) Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
EP4234027A3 (en) Prefusion piv f immunogens and their use
IN2014DN09351A (es)
WO2021222639A3 (en) Recombinant human metapneumovirus f proteins and their use
MX2014012234A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
BR112018010639A2 (pt) método de transfecção transitória para produção retroviral.
MX2020001282A (es) Polipeptidos que tienen actividad trehalasa y uso de los mismos en proceso de produccion de productos de fermentacion.
MY169049A (en) Microorganisms for producing putrescine and process for producing putrescine using them
MX2017013174A (es) Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos.
NZ712713A (en) Attenuated swine influenza vaccines and methods of making and use thereof
CN106687579A8 (zh) 产生二胺的微生物和使用该微生物产生二胺的方法
MY181148A (en) Microorganisms for producing diamine and process for producing diamine using them
BR112022011422A2 (pt) Imunógenos para vírus da caxumba e do sarampo e seus usos
PH12020551876A1 (en) Nucleic acid for treating mite allergy